Linked Life Data

10850309

Source:http://linkedlifedata.com/resource/pubmed/id/10850309

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2000-6-30
pubmed:abstractText
Certain treatments such as allogeneic bone marrow transplantation or the more recent technique of nonablative donor lymphocyte infusions may offer curative opportunities to a small number of patients with low grade lymphoma. For the majority of patients, though, this disease remains incurable. Therefore, management must balance toxicity with efficacy. Rituximab is a new form of treatment with a highly favorable toxicity profile, and its short course of therapy on an outpatient basis has a positive effect on quality of life. Rituximab and related radioimmunotherapy strategies represent new directions for the treatment of non-Hodgkin's lymphoma. Other forms of therapy, including vaccines or modulators of cell activity, promise to further improve the therapeutic index for lymphoma by increasing the specificity of treatment with less toxicity. An added bonus of rituximab is its potential to help unlock some of the mysteries of cellular regulation and dysregulation of normal and malignant B cells.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1084-9785
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
237-40
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Rituximab immunotherapy.
pubmed:publicationType
Editorial, Comment, Review